OXT and autism: Furthermore, a study from Ben Ari group suggested that OXT or a selective NKCC1 inhibitor (bumetanide) at birth rescued the behavioral dysfunctions in two animal models of autism that showed deficits in the GABA switch (Eftekhari et al., 2014; Tyzio et al., 2014).